Cargando…

Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada

BACKGROUND: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lachaine, Jean, Beauchemin, Catherine, Mathurin, Karine, Gilbert, Dominique, Beillat, Maud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905654/
https://www.ncbi.nlm.nih.gov/pubmed/24450548
http://dx.doi.org/10.1186/1471-244X-14-16
_version_ 1782301366823157760
author Lachaine, Jean
Beauchemin, Catherine
Mathurin, Karine
Gilbert, Dominique
Beillat, Maud
author_facet Lachaine, Jean
Beauchemin, Catherine
Mathurin, Karine
Gilbert, Dominique
Beillat, Maud
author_sort Lachaine, Jean
collection PubMed
description BACKGROUND: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated with a favourable metabolic profile and minimal weight gain potential. This study aimed to assess the economic impact of asenapine compared to olanzapine in the treatment of BPD in Canada. METHODS: A decision tree combined with a Markov model was constructed to assess the cost-utility of asenapine compared with olanzapine. The decision tree takes into account the occurrence of extrapyramidal symptoms (EPS), the probability of switching to a different antipsychotic, and the probability of gaining weight. The Markov model takes into account long-term metabolic complications including diabetes, hypertension, coronary heart diseases (CHDs), and stroke. Analyses were conducted from both a Canadian Ministry of Health (MoH) and a societal perspective over a five-year time horizon with yearly cycles. RESULTS: In the treatment of BPD, asenapine is a dominant strategy over olanzapine from both a MoH and a societal perspective. In fact, asenapine is associated with lower costs and more quality-adjusted life years (QALYs). Results of the probabilistic sensitivity analysis indicated that asenapine remains a dominant strategy in 99.2% of the simulations, in both a MoH and a societal perspective, and this result is robust to the many deterministic sensitivity analyses performed. CONCLUSIONS: This economic evaluation demonstrates that asenapine is a cost-effective strategy compared to olanzapine in the treatment of BPD in Canada.
format Online
Article
Text
id pubmed-3905654
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39056542014-01-30 Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada Lachaine, Jean Beauchemin, Catherine Mathurin, Karine Gilbert, Dominique Beillat, Maud BMC Psychiatry Research Article BACKGROUND: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated with a favourable metabolic profile and minimal weight gain potential. This study aimed to assess the economic impact of asenapine compared to olanzapine in the treatment of BPD in Canada. METHODS: A decision tree combined with a Markov model was constructed to assess the cost-utility of asenapine compared with olanzapine. The decision tree takes into account the occurrence of extrapyramidal symptoms (EPS), the probability of switching to a different antipsychotic, and the probability of gaining weight. The Markov model takes into account long-term metabolic complications including diabetes, hypertension, coronary heart diseases (CHDs), and stroke. Analyses were conducted from both a Canadian Ministry of Health (MoH) and a societal perspective over a five-year time horizon with yearly cycles. RESULTS: In the treatment of BPD, asenapine is a dominant strategy over olanzapine from both a MoH and a societal perspective. In fact, asenapine is associated with lower costs and more quality-adjusted life years (QALYs). Results of the probabilistic sensitivity analysis indicated that asenapine remains a dominant strategy in 99.2% of the simulations, in both a MoH and a societal perspective, and this result is robust to the many deterministic sensitivity analyses performed. CONCLUSIONS: This economic evaluation demonstrates that asenapine is a cost-effective strategy compared to olanzapine in the treatment of BPD in Canada. BioMed Central 2014-01-22 /pmc/articles/PMC3905654/ /pubmed/24450548 http://dx.doi.org/10.1186/1471-244X-14-16 Text en Copyright © 2014 Lachaine et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lachaine, Jean
Beauchemin, Catherine
Mathurin, Karine
Gilbert, Dominique
Beillat, Maud
Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
title Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
title_full Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
title_fullStr Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
title_full_unstemmed Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
title_short Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
title_sort cost-effectiveness of asenapine in the treatment of bipolar disorder in canada
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905654/
https://www.ncbi.nlm.nih.gov/pubmed/24450548
http://dx.doi.org/10.1186/1471-244X-14-16
work_keys_str_mv AT lachainejean costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada
AT beauchemincatherine costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada
AT mathurinkarine costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada
AT gilbertdominique costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada
AT beillatmaud costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada